Myelodysplastic Syndromes
Also known as: MDS, Disorder, Syndrome, Diseases, Condition
Methodology & AI Transparency ⓘ
Myelodysplastic Syndromes Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Your bone marrow is the spongy tissue inside some of your bones, such as your hip and thigh bones.
- 2 Real-world patient consensus: Diagnostic registry D46.9: Myelodysplastic Syndromes is managed within Blood & Anemia (aka MDS).
- 3 Typical cash cost range: Clinicians assessing Myelodysplastic Syndromes focus on primary platelet/megakaryocyte dysregulation in Myelodysplastic Syndromes (D46.9: or inherited/acquired coagulation) and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Myelodysplastic Syndromes: maintaining Serum Ferritin & in Myelodysplastic Syndromes (D46.9: Transferrin Saturation) within Ferritin 50–150 ng/mL; TSAT 20%–45% (D46.9).
Ask our AI Specialists anything about Myelodysplastic Syndromes
What Is Myelodysplastic Syndromes?
Your bone marrow is the spongy tissue inside some of your bones, such as your hip and thigh bones. It contains immature cells, called stem cells. The stem cells can develop into the red blood cells that carry oxygen through your body, the white blood cells that fight infections, and the platelets that help with blood clotting. If you have a myelodysplastic syndrome, the stem cells do not mature into healthy blood cells. Many of them die in the bone marrow. This means that you do not have enough healthy cells, which can lead to infection, anemia , or easy bleeding.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Myelodysplastic Syndromes (D46.9) features primary platelet/megakaryocyte dysregulation in Myelodysplastic Syndromes (D46.9: or inherited/acquired coagulation). Cross-referenced with NIH MeSH (Myelodysplastic Syndromes), therapeutic stabilization in blood & anemia is verified against Vitamin B12, Folate in Myelodysplastic Syndromes (D46.9: & Reticulocyte Count).
Common Symptoms & Clinical Signs
- • Shortness of breath
- • Weakness or feeling tired
- • Presentation of Myelodysplastic Syndromes (D46.9): restless legs, ice in Myelodysplastic Syndromes (D46.9: craving)
- • Secondary Myelodysplastic Syndromes clinical sign: easy bruising, prolonged in Myelodysplastic Syndromes (D46.9: bleeding from minor)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Myelodysplastic Syndromes Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | D46.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Anemia, Clotting & Blood Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Serum Ferritin & in Myelodysplastic Syndromes (D46.9: Transferrin Saturation) | Ferritin 50–150 ng/mL; TSAT 20%–45% (D46.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Vitamin B12, Folate in Myelodysplastic Syndromes (D46.9: & Reticulocyte Count) | B12 > 500 pg/mL; appropriate marrow response (D46.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Platelet Count & in Myelodysplastic Syndromes (D46.9: PT/INR / aPTT) | Platelets 150–400 x10^3/uL (D46.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Myelodysplastic Syndromes
Treatment selection for Myelodysplastic Syndromes depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Myelodysplastic Syndromes)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Roxadustat versus placebo for patients with lower-risk myelodysplastic syndrome:: What a 272-Participant Study Found Despite MATTERHORN not meeting its primary endpoint, a numerically higher TI rate was achieved with roxadustat treatment compared with placebo. American journal of hematology • 2024-09-15 • Phase III Randomized Trial | N = 272 | 93/100 | PMID 38884137 ↗ |
| Can This Approach Help? Inside the Latest Research on Phase I Clinical Trial of SyB C-1101 in Patients With Myelodysplastic Syndrome - Registered in the U.S. ClinicalTrials.gov Registry (NIH NLM) • 2014-12-01 • Completed Human Clinical Trial (NCT) | N = 1 | 89/100 | PMID NCT02002936 ↗ |
| Can This Approach Help? Inside the Latest Research on Roxadustat for the treatment of anemia in patients with lower-risk There were no fatalities or progression to acute myeloid leukemia. American journal of hematology • 2022-02-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34724251 ↗ |
| Can This Approach Help? Inside the Latest Research on Imetelstat improves patient-reported outcomes and quality of life in lower-risk 37%, 41%, and 44%, respectively; P<0.001, P=0.004, and P=0.002) and QOL across different measures of response (43-53% vs. Haematologica • 2026-07-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41568521 ↗ |
| Can This Approach Help? Inside the Latest Research on Modulation of the clonal burden in patients with lower-risk myelodysplastic Lastly, 60% of patients with ≥1-year RBC-TI had ≥50% reduction in telomerase activity/human telomerase reverse transcriptase RNA. Leukemia • 2026-02-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41526614 ↗ |
Myelodysplastic Syndromes Patient Community & “People Like Me” Threads
Filter Myelodysplastic Syndromes community threads and patient logs by age, biological sex, dosage, and treatment duration.